Cancer risk in immune-mediated inflammatory diseases (IMID).

[en] Inflammation and cancer have a profound yet ambiguous relationship. Inflammation - especially chronic inflammation - has protumorigenic effects, but inflammatory cells also mediate an immune response against the tumor and immunosuppression is known to increase the risk for certain tumors.This article reviews current literature on the role of inflammation in cancer and the cancer risk in immune-mediated inflammatory diseases (IMIDs). We discuss the effect on cancer risk of different drug classes used in the treatment of IMIDs treatment, including biologicals such as tumor necrosis factor (TNF) inhibitors.Overall cancer incidence and mortality risk are similar to the general population in inflammatory bowel disease (IBD), and slightly increased for rheumatoid arthritis and psoriasis, with risk profiles differing for different tumor types. Increased risk for non-melanoma skin cancer is associated with thiopurine treatment in IBD, with the combination of anti-TNF and methotrexate in rheumatoid arthritis and with PUVA, cyclosporine and anti-TNF treatment in psoriasis. Data on the safety of using biologic or immunosuppressant therapy in IMID patients with a history of cancer are scarce.This review provides clinicians with a solid background to help them in making decisions about treatment of immune-mediated diseases in patients with a tumor history.This article is related to another review article in Molecular Cancer: http://www.molecular-cancer.com/content/12/1/86.

Disciplines :

Oncology

Author, co-author :

Beyaert, Rudi

Beaugerie, Laurent

Van Assche, Gert

Brochez, Lieve

Renauld, Jean-Christophe

Viguier, Manuelle

Cocquyt, Veronique

JERUSALEM, Guy ; Centre Hospitalier Universitaire de Liège - CHU > Oncologie médicale

Machiels, Jean-Pascal

Prenen, Hans

More authors (3 more)

Language :

English

Title :

Cancer risk in immune-mediated inflammatory diseases (IMID).

Publication date :

2013

Journal title :

Molecular Cancer

eISSN :

1476-4598

Publisher :

BioMed Central, United Kingdom

Volume :

Issue :

Pages :

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 26 December 2013

Statistics

Number of views

94 (9 by ULiège)

Number of downloads

323 (4 by ULiège)

More statistics

Scopus citations^®

101

Scopus citations^®
without self-citations

OpenCitations

Bibliography

Williams JP, Meyers JA. Immune-mediated inflammatory disorders (I.M.I.D.s): the economic and clinical costs. Am J Manag Care 2002, 8(21 Suppl):S664-S681. quiz S682-5.
Mantovani A. Cancer: Inflaming metastasis. Nature 2009, 457:36-37.
Grivennikov SI, Karin M. Inflammation and oncogenesis: a vicious connection. Curr Opin Genet Dev 2010, 20:65-71. 10.1016/j.gde.2009.11.004, 2821983, 20036794.
Solinas G, Germano G, Mantovani A, Allavena P. Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation. J Leukoc Biol 2009, 86:1065-1073. 10.1189/jlb.0609385, 19741157.
Burnet FM. Immunological surveillance in neoplasia. Transplant Rev 1971, 7:3-25.
Bui JD, Schreiber RD. Cancer immunosurveillance, immunoediting and inflammation: independent or interdependent processes?. Curr Opin Immunol 2007, 19:203-208. 10.1016/j.coi.2007.02.001, 17292599.
Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu Rev Immunol 2004, 22:329-360. 10.1146/annurev.immunol.22.012703.104803, 15032581.
Nakachi K, Hayashi T, Imai K, Kusunoki Y. Perspectives on cancer immuno-epidemiology. Cancer Sci 2004, 95:921-929. 10.1111/j.1349-7006.2004.tb03178.x, 15596039.
Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ, Schreiber RD. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001, 410:1107-1111. 10.1038/35074122, 11323675.
Smyth MJ, Thia KY, Street SE, Cretney E, Trapani JA, Taniguchi M, Kawano T, Pelikan SB, Crowe NY, Godfrey DI. Differential tumor surveillance by natural killer (NK) and NKT cells. J Exp Med 2000, 191:661-668. 10.1084/jem.191.4.661, 2195840, 10684858.
Street SEA, Trapani JA, MacGregor D, Smyth MJ. Suppression of Lymphoma and Epithelial Malignancies Effected by Interferon. J Exp Med 2002, 196:129-134. 10.1084/jem.20020063, 2194011, 12093877.
Engel AM, Svane IM, Rygaard J, Werdelin O. MCA sarcomas induced in scid mice are more immunogenic than MCA sarcomas induced in congenic, immunocompetent mice. Scand J Immunol 1997, 45:463-470. 10.1046/j.1365-3083.1997.d01-419.x, 9160088.
Svane IM, Engel AM, Nielsen MB, Ljunggren HG, Rygaard J, Werdelin O. Chemically induced sarcomas from nude mice are more immunogenic than similar sarcomas from congenic normal mice. Eur J Immunol 1996, 26:1844-1850. 10.1002/eji.1830260827, 8765030.
Müller-Hermelink N, Braumüller H, Pichler B, Wieder T, Mailhammer R, Schaak K, Ghoreschi K, Yazdi A, Haubner R, Sander CA, Mocikat R, Schwaiger M, Förster I, Huss R, Weber WA, Kneilling M, Röcken M. TNFR1 signaling and IFN-gamma signaling determine whether T cells induce tumor dormancy or promote multistage carcinogenesis. Cancer Cell 2008, 13:507-518. 10.1016/j.ccr.2008.04.001, 18538734.
Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 2008, 454:436-444. 10.1038/nature07205, 18650914.
Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow?. Lancet 2001, 357:539-545. 10.1016/S0140-6736(00)04046-0, 11229684.
Karin M, Greten FR. NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 2005, 5:749-759. 10.1038/nri1703, 16175180.
Rothwell PM, Price JF, Fowkes FGR, Zanchetti A, Roncaglioni MC, Tognoni G, Lee R, Belch JFF, Wilson M, Mehta Z, Meade TW. Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet 2012, 379:1602-1612. 10.1016/S0140-6736(11)61720-0, 22440946.
Jacobs EJ, Newton CC, Gapstur SM, Thun MJ. Daily aspirin use and cancer mortality in a large US cohort. J Natl Cancer Inst 2012, 104:1208-1217. 10.1093/jnci/djs318, 22888140.
Baron JA. Aspirin and cancer: trials and observational studies. J Natl Cancer Inst 2012, 104:1199-1200. 10.1093/jnci/djs338, 22888142.
Pasche B. Differential effects of aspirin before and after diagnosis of colorectal cancer. JAMA 2013, 309:2598-2599. 10.1001/jama.2013.6600, 23800937.
Kaiser J. Will an aspirin a day keep cancer away?. Science 2012, 337:1471-1473. 10.1126/science.337.6101.1471, 22997320.
Zumsteg A, Christofori G. Corrupt policemen: inflammatory cells promote tumor angiogenesis. Curr Opin Oncol 2009, 21:60-70. 10.1097/CCO.0b013e32831bed7e, 19125020.
Zamarron BF, Chen W. Dual roles of immune cells and their factors in cancer development and progression. Int J Biol Sci 2011, 7:651-658. 3107473, 21647333.
Pastuła A, Marcinkiewicz J. Myeloid-derived suppressor cells: a double-edged sword?. Int J Exp Pathol 2011, 92:73-78. 10.1111/j.1365-2613.2010.00754.x, 3081509, 21314739.
Ben-Neriah Y, Karin M. Inflammation meets cancer, with NF-κB as the matchmaker. Nat Immunol 2011, 12:715-723.
Barnes PJ, Karin M. Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997, 336:1066-1071. 10.1056/NEJM199704103361506, 9091804.
Hayden MS, Ghosh S. NF-κB, the first quarter-century: remarkable progress and outstanding questions. Genes Dev 2012, 26:203-234. 10.1101/gad.183434.111, 3278889, 22302935.
Karin M, Cao Y, Greten FR, Li Z-W. NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2002, 2:301-310.
Askling J, Fored CM, Baecklund E, Brandt L, Backlin C, Ekbom A, Sundström C, Bertilsson L, Cöster L, Geborek P, Jacobsson LT, Lindblad S, Lysholm J, Rantapää-Dahlqvist S, Saxne T, Klareskog L, Feltelius N. Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists. Ann Rheum Dis 2005, 64:1414-1420. 10.1136/ard.2004.033241, 1755232, 15843454.
Zhang J, Wu P, Hu Y. Clinical and marketed proteasome inhibitors for cancer treatment. Curr Med Chem 2013, 20:2537-2551. 10.2174/09298673113209990122, 23531219.
Askling J, Fored CM, Brandt L, Baecklund E, Bertilsson L, Feltelius N, Cöster L, Geborek P, Jacobsson LT, Lindblad S, Lysholm J, Rantapää-Dahlqvist S, Saxne T, Klareskog L. Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists. Ann Rheum Dis 2005, 64:1421-1426. 10.1136/ard.2004.033993, 1755244, 15829572.
Smitten AL, Simon TA, Hochberg MC, Suissa S. A meta-analysis of the incidence of malignancy in adult patients with rheumatoid arthritis. Arthritis Res Ther 2008, 10:R45. 10.1186/ar2404, 2453765, 18433475.
Baecklund E, Iliadou A, Askling J, Ekbom A, Backlin C, Granath F, Catrina AI, Rosenquist R, Feltelius N, Sundström C, Klareskog L. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum 2006, 54:692-701. 10.1002/art.21675, 16508929.
Loftus EV. Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences. Gastroenterology 2004, 126:1504-1517. 10.1053/j.gastro.2004.01.063, 15168363.
Kristinsson SY, Landgren O, Samuelsson J, Björkholm M, Goldin LR. Autoimmunity and the risk of myeloproliferative neoplasms. Haematologica 2010, 95:1216-1220. 10.3324/haematol.2009.020412, 2895049, 20053870.
Watanabe T, Soga K, Hirono H, Hasegawa K, Shibasaki K, Kawai H, Aoyagi Y. Features of hepatocellular carcinoma in cases with autoimmune hepatitis and primary biliary cirrhosis. World J Gastroenterol 2009, 15:231-239. 10.3748/wjg.15.231, 2653317, 19132775.
Wong RJ, Gish R, Frederick T, Bzowej N, Frenette C. Development of hepatocellular carcinoma in autoimmune hepatitis patients: a case series. Dig Dis Sci 2011, 56:578-585. 10.1007/s10620-010-1444-6, 21046244.
Goldacre MJ, Wotton CJ, Yeates D, Seagroatt V, Jewell D. Cancer in patients with ulcerative colitis, Crohn's disease and coeliac disease: record linkage study. Eur J Gastroenterol Hepatol 2008, 20:297-304. 10.1097/MEG.0b013e3282f2a5e2, 18334873.
Landgren AM, Landgren O, Gridley G, Dores GM, Linet MS, Morton LM. Autoimmune disease and subsequent risk of developing alimentary tract cancers among 4.5 million US male veterans. Cancer 2011, 117:1163-1171. 10.1002/cncr.25524, 3052786, 21381009.
Silano M, Volta U, Mecchia AM, Dessì M, Di-Benedetto R, De-Vincenzi M. Delayed diagnosis of coeliac disease increases cancer risk. BMC Gastroenterol 2007, 7:8. 10.1186/1471-230X-7-8, 2140155, 17349035.
Pedersen N, Duricova D, Elkjaer M, Gamborg M, Munkholm P, Jess T. Risk of extra-intestinal cancer in inflammatory bowel disease: meta-analysis of population-based cohort studies. Am J Gastroenterol 2010, 105:1480-1487. 10.1038/ajg.2009.760, 20332773.
Laukoetter MG, Mennigen R, Hannig CM, Osada N, Rijcken E, Vowinkel T, Krieglstein CF, Senninger N, Anthoni C, Bruewer M. Intestinal cancer risk in Crohn's disease: a meta-analysis. J Gastrointest Surg 2011, 15:576-583. 10.1007/s11605-010-1402-9, 21152994.
Canavan C, Abrams KR, Mayberry J. Meta-analysis: colorectal and small bowel cancer risk in patients with Crohn's disease. Aliment Pharmacol Ther 2006, 23:1097-1104. 10.1111/j.1365-2036.2006.02854.x, 16611269.
Hemminki K, Li X, Sundquist J, Sundquist K. Cancer risks in Crohn disease patients. Ann Oncol 2009, 20:574-580.
Szekanecz Z, Szekanecz E, Bakó G, Shoenfeld Y. Malignancies in autoimmune rheumatic diseases - a mini-review. Gerontology 2011, 57:3-10. 10.1159/000314634, 20453490.
Prizment AE, Alonso A, Folsom AR, Ahmed RL, Virnig BA, Warshaw EM, Anderson KE. Association between psoriasis and incident cancer: the Iowa's Women's Health Study. Cancer Causes Control 2011, 22:1003-1010. 10.1007/s10552-011-9773-0, 3175809, 21553077.
Hannuksela-Svahn A, Pukkala E, Läärä E, Poikolainen K, Karvonen J. Psoriasis, its treatment, and cancer in a cohort of Finnish patients. J Invest Dermatol 2000, 114:587-590. 10.1046/j.1523-1747.2000.00898.x, 10692122.
Margolis D, Bilker W, Hennessy S, Vittorio C, Santanna J, Strom BL. The risk of malignancy associated with psoriasis. Arch Dermatol 2001, 137:778-783.
Chen Y-J, Wu C-Y, Chen T-J, Shen J-L, Chu S-Y, Wang C-B, Chang Y-T. The risk of cancer in patients with psoriasis: a population-based cohort study in Taiwan. J Am Acad Dermatol 2011, 65:84-91. 10.1016/j.jaad.2010.04.046, 21458106.
Lanoy E, Engels EA. Skin cancers associated with autoimmune conditions among elderly adults. Br J Cancer 2010, 103:112-114. 10.1038/sj.bjc.6605733, 2894998,2894998, 20551958.
Boffetta P, Gridley G, Lindelöf B. Cancer risk in a population-based cohort of patients hospitalized for psoriasis in Sweden. J Invest Dermatol 2001, 117:1531-1537. 10.1046/j.0022-202x.2001.01520.x, 11886519.
Ji J, Shu X, Sundquist K, Sundquist J, Hemminki K. Cancer risk in hospitalised psoriasis patients: a follow-up study in Sweden. Br J Cancer 2009, 100:1499-1502. 10.1038/sj.bjc.6605027, 2694437, 19352386.
Söderberg KC, Jonsson F, Winqvist O, Hagmar L, Feychting M. Autoimmune diseases, asthma and risk of haematological malignancies: a nationwide case-control study in Sweden. Eur J Cancer 2006, 42:3028-3033. 10.1016/j.ejca.2006.04.021, 16945522.
Gelfand JM, Berlin J, Van-Voorhees A, Margolis DJ. Lymphoma rates are low but increased in patients with psoriasis: results from a population-based cohort study in the United Kingdom. Arch Dermatol 2003, 139:1425-1429. 10.1001/archderm.139.11.1425, 14623702.
Pouplard C, Brenaut E, Horreau C, Barnetche T, Misery L, Richard M, Aractingi S, Aubin F, Cribier B, Joly P, Jullien D, Le-Maître M, Ortonne J-P, Paul C. Risk of cancer in psoriasis: a systematic review and meta-analysis of epidemiological studies. J Eur Acad Dermatol Venereol 2013, 27(Suppl 3):36-46.
Richard M, Barnetche T, Horreau C, Brenaut E, Pouplard C, Aractingi S, Aubin F, Cribier B, Joly P, Jullien D, Le-Maître M, Misery L, Ortonne J-P, Paul C. Psoriasis, cardiovascular events, cancer risk and alcohol use: evidence-based recommendations based on systematic review and expert opinion. J Eur Acad Dermatol Venereol 2013, 27(Suppl 3):2-11.
Askling J, Brandt L, Lapidus A, Karlén P, Björkholm M, Löfberg R, Ekbom A. Risk of haematopoietic cancer in patients with inflammatory bowel disease. Gut 2005, 54:617-622. 10.1136/gut.2004.051771, 1774486, 15831904.
Boffetta P, Rabkin CS, Gridley G. A cohort study of cancer among sarcoidosis patients. Int J Cancer 2009, 124:2697-2700. 10.1002/ijc.24261, 19230028.
Liu H, Ding Q, Yang K, Zhang T, Li G, Wu G. Meta-analysis of systemic lupus erythematosus and the risk of cervical neoplasia. Rheumatology (Oxford) 2011, 50:343-348.
Chen Y-J, Chang Y-T, Wang C-B, Wu C-Y. Malignancy in systemic lupus erythematosus: a nationwide cohort study in Taiwan. Am J Med 2010, 123:1150-1156.
Kiss E, Kovacs L, Szodoray P. Malignancies in systemic lupus erythematosus. Autoimmun Rev 2010, 9:195-199. 10.1016/j.autrev.2009.07.004, 19643208.
Rosenthal AK, McLaughlin JK, Gridley G, Nyrén O. Incidence of cancer among patients with systemic sclerosis. Cancer 1995, 76:910-914. 10.1002/1097-0142(19950901)76:5<910::AID-CNCR2820760528>3.0.CO;2-T, 8625197.
Magruder JT, Elahi D, Andersen DK. Diabetes and pancreatic cancer: chicken or egg?. Pancreas 2011, 40:339-351. 10.1097/MPA.0b013e318209e05d, 21412116.
Stevens RJ, Roddam AW, Beral V. Pancreatic cancer in type 1 and young-onset diabetes: systematic review and meta-analysis. Br J Cancer 2007, 96:507-509. 10.1038/sj.bjc.6603571, 2360024, 17224924.
Soetikno RM, Lin OS, Heidenreich PA, Young HS, Blackstone MO. Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis. Gastrointest Endosc 2002, 56:48-54. 10.1067/mge.2002.125367, 12085034.
Veloso FT. Extraintestinal manifestations of inflammatory bowel disease: do they influence treatment and outcome?. World J Gastroenterol 2011, 17:2702-2707. 3122258, 21734777.
Bernstein CN, Blanchard JF, Kliewer E, Wajda A. Cancer risk in patients with inflammatory bowel disease: a population-based study. Cancer 2001, 91:854-862. 10.1002/1097-0142(20010215)91:4<854::AID-CNCR1073>3.0.CO;2-Z, 11241255.
Thomas T, Abrams KA, Robinson RJ, Mayberry JF. Meta-analysis: cancer risk of low-grade dysplasia in chronic ulcerative colitis. Aliment Pharmacol Ther 2007, 25:657-668. 10.1111/j.1365-2036.2007.03241.x, 17311598.
Rutter MD, Saunders BP, Wilkinson KH, Rumbles S, Schofield G, Kamm MA, Williams CB, Price AB, Talbot IC, Forbes A. Cancer surveillance in longstanding ulcerative colitis: endoscopic appearances help predict cancer risk. Gut 2004, 53:1813-1816. 10.1136/gut.2003.038505, 1774334, 15542520.
Gupta RB, Harpaz N, Itzkowitz S, Hossain S, Matula S, Kornbluth A, Bodian C, Ullman T. Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study. Gastroenterology 2007, 133:1099-1105. quiz 1340-1, 10.1053/j.gastro.2007.08.001, 2175077, 17919486.
Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med 2009, 361:496-509. 10.1056/NEJMra0804595, 19641206.
El-Gabalawy H, Guenther LC, Bernstein CN. Epidemiology of immune-mediated inflammatory diseases: incidence, prevalence, natural history, and comorbidities. J Rheumatol Suppl 2010, 85(Imid):2-10.
Naldi L. Malignancy concerns with psoriasis treatments using phototherapy, methotrexate, cyclosporin, and biologics: facts and controversies. Clin Dermatol 2010, 28:88-92. 10.1016/j.clindermatol.2009.03.003, 20082957.
Patel RV, Clark LN, Lebwohl M, Weinberg JM. Treatments for psoriasis and the risk of malignancy. J Am Acad Dermatol 2009, 60:1001-1017. 10.1016/j.jaad.2008.12.031, 19344980.
Stern RS. Lymphoma risk in psoriasis: results of the PUVA follow-up study. Arch Dermatol 2006, 142:1132-1135. 10.1001/archderm.142.9.1132, 16983000.
Väkevä L, Reitamo S, Pukkala E, Sarna S, Ranki A. Long-term follow-up of cancer risk in patients treated with short-term cyclosporine. Acta Derm Venereol 2008, 88:117-120. 10.2340/00015555-0360, 18311436.
Lee H-M, Sugino H, Nishimoto N. Cytokine networks in systemic lupus erythematosus. J Biomed Biotechnol 2010, 2010:676284. 2857803, 20414360.
Smith PP, Gordon C. Systemic lupus erythematosus: clinical presentations. Autoimmun Rev 2010, 10:43-45. 10.1016/j.autrev.2010.08.016, 20850569.
Bernatsky S, Ramsey-Goldman R, Foulkes WD, Gordon C, Clarke AE. Breast, ovarian, and endometrial malignancies in systemic lupus erythematosus: a meta-analysis. Br J Cancer 2011, 104:1478-1481. 10.1038/bjc.2011.115, 3101932, 21487409.
Dinarello CA. Anti-inflammatory Agents: Present and Future. Cell 2010, 140:935-50. 10.1016/j.cell.2010.02.043, 3752337, 20303881.
Martinez OM, De-Gruijl FR. Molecular and immunologic mechanisms of cancer pathogenesis in solid organ transplant recipients. Am J Transplant 2008, 8:2205-2211. 10.1111/j.1600-6143.2008.02368.x, 18801025.
Burnet FM. The concept of immunological surveillance. Prog Exp Tumor Res 1970, 13:1-27.
Burnet FM. Implications of immunological surveillance for cancer therapy. Isr J Med Sci 1971, 7:9-16.
Karran P, Attard N. Thiopurines in current medical practice: molecular mechanisms and contributions to therapy-related cancer. Nat Rev Cancer 2008, 8:24-36. 10.1038/nrc2292, 18097462.
Beaugerie L, Brousse N, Bouvier AM, Colombel JF, Lémann M, Cosnes J, Hébuterne X, Cortot A, Bouhnik Y, Gendre JP, Simon T, Maynadié M, Hermine O, Faivre J, Carrat F. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet 2009, 374:1617-1625. 10.1016/S0140-6736(09)61302-7, 19837455.
Long MD, Herfarth HH, Pipkin CA, Porter CQ, Sandler RS, Kappelman MD. Increased risk for non-melanoma skin cancer in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2010, 8:268-274. 10.1016/j.cgh.2009.11.024, 2838486, 20005977.
Kandiel A, Fraser AG, Korelitz BI, Brensinger C, Lewis JD. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut 2005, 54:1121-5. 10.1136/gut.2004.049460, 1774897, 16009685.
Setshedi M, Epstein D, Winter TA, Myer L, Watermeyer G, Hift R. Use of thiopurines in the treatment of inflammatory bowel disease is associated with an increased risk of non-melanoma skin cancer in an at-risk population: a cohort study. J Gastroenterol Hepatol 2012, 27:385-389. 10.1111/j.1440-1746.2011.06865.x, 21793904.
Paul CF, Ho VC, McGeown C, Christophers E, Schmidtmann B, Guillaume J-C, Lamarque V, Dubertret L. Risk of malignancies in psoriasis patients treated with cyclosporine: a 5 y cohort study. J Invest Dermatol 2003, 120:211-216. 10.1046/j.1523-1747.2003.12040.x, 12542524.
Masunaga Y, Ohno K, Ogawa R, Hashiguchi M, Echizen H, Ogata H. Meta-analysis of risk of malignancy with immunosuppressive drugs in inflammatory bowel disease. Ann Pharmacother 2007, 41:21-28.
Buchbinder R, Barber M, Heuzenroeder L, Wluka AE, Giles G, Hall S, Harkness A, Lewis D, Littlejohn G, Miller MH, Ryan PFJ, Jolley D. Incidence of melanoma and other malignancies among rheumatoid arthritis patients treated with methotrexate. Arthritis Rheum 2008, 59:794-799. 10.1002/art.23716, 18512713.
Salliot C, van der-Heijde D. Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research. Ann Rheum Dis 2009, 68:1100-1104. 10.1136/ard.2008.093690, 2689525, 19060002.
Krathen MS, Gottlieb AB, Mease PJ. Pharmacologic immunomodulation and cutaneous malignancy in rheumatoid arthritis, psoriasis, and psoriatic arthritis. J Rheumatol 2010, 37:2205-2215. 10.3899/jrheum.100041, 20810498.
Brodsky RA. High dose cyclophosphamide treatment for autoimmune disorders. Sci World J 2002, 2:1808-15.
Vlaovic P, Jewett MAS. Cyclophosphamide-induced bladder cancer. Can J Urol 1999, 6:745-748.
Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci U S A 1975, 72:3666-3670. 10.1073/pnas.72.9.3666, 433057, 1103152.
Fiers W, Beyaert R, Brouckaert P, Everaerdt B, Haegeman C, Suffys P, Tavernier J, Vanhaesebroeck B. TNF: its potential as an antitumour agent. Dev Biol Stand 1988, 69:143-151.
Van-Horssen R, Ten-Hagen TLM, Eggermont AMM. TNF-alpha in cancer treatment: molecular insights, antitumor effects, and clinical utility. Oncologist 2006, 11:397-408. 10.1634/theoncologist.11-4-397, 16614236.
Balkwill F. Tumour necrosis factor and cancer. Nat Rev Cancer 2009, 9:361-371. 10.1038/nrc2628, 19343034.
Cantaert T, Baeten D, Tak PP, Van-Baarsen LGM. Type I IFN and TNFα cross-regulation in immune-mediated inflammatory disease: basic concepts and clinical relevance. Arthritis Res Ther 2010, 12:219. 10.1186/ar3150, 2991015, 21062511.
Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther 2008, 117:244-279. 10.1016/j.pharmthera.2007.10.001, 18155297.
Wei Y, Liu F, Li B, Chen X, Ma Y, Yan L, Wen T, Xu M, Wang W, Yang J. Polymorphisms of tumor necrosis factor-alpha and hepatocellular carcinoma risk: a HuGE systematic review and meta-analysis. Dig Dis Sci 2011, 56:2227-2236. 10.1007/s10620-011-1617-y, 21336601.
Yang Y, Luo C, Feng R, Bi S. The TNF-α, IL-1B and IL-10 polymorphisms and risk for hepatocellular carcinoma: a meta-analysis. J Cancer Res Clin Oncol 2011, 137:947-952. 10.1007/s00432-010-0959-8, 21107607.
Guo YM, Yu WW, Shen XZ. Tumor necrosis factor rs361525 (-238G > A) polymorphism contributes to hepatocellular carcinoma susceptibility. Saudi Med J 2010, 31:1101-1105.
Guo Y-M, Wei W-Y, Shen X-Z. Tumour necrosis factor 308 polymorphisms and hepatocellular carcinoma risk: a meta-analysis. Hepatogastroenterology 2010, 57:926-31.
Skibola CF, Bracci PM, Nieters A, Brooks-Wilson A, De-Sanjosé S, Hughes AM, Cerhan JR, Skibola DR, Purdue M, Kane E, Lan Q, Foretova L, Schenk M, Spinelli JJ, Slager SL, De-Roos AJ, Smith MT, Roman E, Cozen W, Boffetta P, Kricker A, Zheng T, Lightfoot T, Cocco P, Benavente Y, Zhang Y, Hartge P, Linet MS, Becker N, Brennan P, et al. Tumor necrosis factor (TNF) and lymphotoxin-alpha (LTA) polymorphisms and risk of non-Hodgkin lymphoma in the InterLymph Consortium. Am J Epidemiol 2010, 171:267-276. 10.1093/aje/kwp383, 2842204, 20047977.
Fang F, Yao L, Yu XJ, Yu L, Wu Q, Yu L. TNFalpha -308 G/A polymorphism is associated with breast cancer risk: a meta-analysis involving 10,184 cases and 12,911 controls. Breast Cancer Res Treat 2010, 122:267-271. 10.1007/s10549-009-0698-1, 20035378.
Zhang J, Dou C, Song Y, Ji C, Gu S, Xie Y, Mao Y. Polymorphisms of tumor necrosis factor-alpha are associated with increased susceptibility to gastric cancer: a meta-analysis. J Hum Genet 2008, 53:479-489. 10.1007/s10038-008-0273-3, 18350251.
Taylor PC. Pharmacology of TNF blockade in rheumatoid arthritis and other chronic inflammatory diseases. Curr Opin Pharmacol 2010, 10:308-315. 10.1016/j.coph.2010.01.005, 20172761.
Lin J, Ziring D, Desai S, Kim S, Wong M, Korin Y, Braun J, Reed E, Gjertson D, Singh RR. TNFalpha blockade in human diseases: an overview of efficacy and safety. Clin Immunol 2008, 126:13-30. 10.1016/j.clim.2007.08.012, 2291511, 17916445.
Bickston SJ, Lichtenstein GR, Arseneau KO, Cohen RB, Cominelli F. The relationship between infliximab treatment and lymphoma in Crohn's disease. Gastroenterology 1999, 117:1433-1437. 10.1016/S0016-5085(99)70294-5, 10579985.
Brown SL, Greene MH, Gershon SK, Edwards ET, Braun MM. Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum 2002, 46:3151-3158. 10.1002/art.10679, 12483718.
Alcaín G, Andrade RJ, Queipo de Llano MP, Moreno MJ, García-Cortés M, Franquelo E. Acute leukemia after infliximab therapy. Am J Gastroenterol 2003, 98:2577.
Bakland G, Nossent H. Acute myelogenous leukaemia following etanercept therapy. Rheumatology (Oxford) 2003, 42:900-901.
Wolfe F, Michaud K. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum 2004, 50:1740-1751. 10.1002/art.20311, 15188349.
Wolfe F, Michaud K. Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study. Arthritis Rheum 2007, 56:2886-2895. 10.1002/art.22864, 17729297.
Wolfe F, Michaud K. The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation. Arthritis Rheum 2007, 56:1433-1439. 10.1002/art.22579, 17469100.
Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006, 295:2275-2285. 10.1001/jama.295.19.2275, 16705109.
Peyrin-Biroulet L, Deltenre P, De-Suray N, Branche J, Sandborn WJ, Colombel J-F. Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol 2008, 6:644-653. 10.1016/j.cgh.2008.03.014, 18550004.
Leombruno JP, Einarson TR, Keystone EC. The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events. Ann Rheum Dis 2009, 68:1136-1145. 10.1136/ard.2008.091025, 18753157.
Bongartz T, Warren FC, Mines D, Matteson EL, Abrams KR, Sutton AJ. Etanercept therapy in rheumatoid arthritis and the risk of malignancies: a systematic review and individual patient data meta-analysis of randomised controlled trials. Ann Rheum Dis 2009, 68:1177-1183. 10.1136/ard.2008.094904, 19019889.
Siegel CA, Marden SM, Persing SM, Larson RJ, Sands BE. Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis. Clin Gastroenterol Hepatol 2009, 7:874-881. 10.1016/j.cgh.2009.01.004, 2846413, 19558997.
Mariette X, Matucci-Cerinic M, Pavelka K, Taylor P, Van-Vollenhoven R, Heatley R, Walsh C, Lawson R, Reynolds A, Emery P. Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis. Ann Rheum Dis 2011, 70:1895-1904. 10.1136/ard.2010.149419, 21885875.
Dommasch ED, Abuabara K, Shin DB, Nguyen J, Troxel AB, Gelfand JM. The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: a systematic review and meta-analysis of randomized controlled trials. J Am Acad Dermatol 2011, 64:1035-1050. 10.1016/j.jaad.2010.09.734, 3095673, 21315483.
Askling J, Fahrbach K, Nordstrom B, Ross S, Schmid CH, Symmons D. Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data. Pharmacoepidemiol Drug Saf 2011, 20:119-130. 10.1002/pds.2046, 21254282.
Campbell L, Chen C, Bhagat SS, Parker RA, Östör AJK. Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review and meta-analysis of randomized controlled trials. Rheumatology (Oxford) 2011, 50:552-562.
Lopez-Olivo MA, Tayar JH, Martinez-Lopez JA, Pollono EN, Cueto JP, Gonzales-Crespo MR, Fulton S, Suarez-Almazor ME. Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a meta-analysis. JAMA 2012, 308:898-908. 10.1001/2012.jama.10857, 22948700.
Moulis G, Sommet A, Béné J, Montastruc F, Sailler L, Montastruc J-L, Lapeyre-Mestre M. Cancer Risk of Anti-TNF-α at Recommended Doses in Adult Rheumatoid Arthritis: A Meta-Analysis with Intention to Treat and per Protocol Analyses. PLoS One 2012, 7:e48991. 10.1371/journal.pone.0048991, 3498371, 23155441.
Askling J, Van-Vollenhoven RF, Granath F, Raaschou P, Fored CM, Baecklund E, Dackhammar C, Feltelius N, Cöster L, Geborek P, Jacobsson LT, Lindblad S, Rantapää-Dahlqvist S, Saxne T, Klareskog L. Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment?. Arthritis Rheum 2009, 60:3180-3189. 10.1002/art.24941, 19877027.
Singh JA, Noorbaloochi S, Singh G. Golimumab for rheumatoid arthritis. Cochrane Database Syst Rev 2010, CD008341.
Mariette X, Tubach F, Bagheri H, Bardet M, Berthelot JM, Gaudin P, Heresbach D, Martin A, Schaeverbeke T, Salmon D, Lemann M, Hermine O, Raphael M, Ravaud P. Lymphoma in patients treated with anti-TNF: results of the 3-year prospective French RATIO registry. Ann Rheum Dis 2010, 69:400-408. 10.1136/ard.2009.117762, 2925048, 19828563.
Deepak P, Sifuentes H, Sherid M, Stobaugh D, Sadozai Y, Ehrenpreis ED. T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-α) inhibitors: results of the REFURBISH study. Am J Gastroenterol 2013, 108:99-105. 10.1038/ajg.2012.334, 23032984.
Dunn LK, Feldman SR. Alefacept treatment for chronic plaque psoriasis. Skin Therapy Lett 2010, 15:1-3.
Goffe B, Papp K, Gratton D, Krueger GG, Darif M, Lee S, Bozic C, Sweetser MT, Ticho B. An integrated analysis of thirteen trials summarizing the long-term safety of alefacept in psoriasis patients who have received up to nine courses of therapy. Clin Ther 2005, 27:1912-1921. 10.1016/j.clinthera.2005.12.007, 16507377.
Bagust A, Boland A, Hockenhull J, Fleeman N, Greenhalgh J, Dundar Y, Proudlove C, Kennedy T, Moots R, Williamson P, Dickson R. Rituximab for the treatment of rheumatoid arthritis. Health Technol Assess 2009, 13(Suppl 2):23-29.
Slimani S, Lukas C, Combe B, Morel J. Rituximab in rheumatoid arthritis and the risk of malignancies: report from a French cohort. Joint Bone Spine 2011, 78:484-487. 10.1016/j.jbspin.2010.11.012, 21196130.
Tarella C, Passera R, Magni M, Benedetti F, Rossi A, Gueli A, Patti C, Parvis G, Ciceri F, Gallamini A, Cortelazzo S, Zoli V, Corradini P, Carobbio A, Mulé A, Bosa M, Barbui A, Di-Nicola M, Sorio M, Caracciolo D, Gianni AM, Rambaldi A. Risk factors for the development of secondary malignancy after high-dose chemotherapy and autograft, with or without rituximab: a 20-year retrospective follow-up study in patients with lymphoma. J Clin Oncol 2011, 29:814-824. 10.1200/JCO.2010.28.9777, 21189387.
Buch MH, Vital EM, Emery P. Abatacept in the treatment of rheumatoid arthritis. Arthritis Res Ther 2008, 10(Suppl 1):S5. 10.1186/ar2416, 2582812, 19007425.
Simon TA, Smitten AL, Franklin J, Askling J, Lacaille D, Wolfe F, Hochberg MC, Qi K, Suissa S. Malignancies in the rheumatoid arthritis abatacept clinical development programme: an epidemiological assessment. Ann Rheum Dis 2009, 68:1819-1826. 10.1136/ard.2008.097527, 2770103, 19054822.
Genovese MC, Schiff M, Luggen M, Le-Bars M, Aranda R, Elegbe A, Dougados M. Longterm safety and efficacy of abatacept through 5 years of treatment in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor inhibitor therapy. J Rheumatol 2012, 39:1546-1554. 10.3899/jrheum.111531, 22798265.
Gandhi M, Alwawi E, Gordon KB. Anti-p40 antibodies ustekinumab and briakinumab: blockade of interleukin-12 and interleukin-23 in the treatment of psoriasis. Semin Cutan Med Surg 2010, 29:48-52. 10.1016/j.sder.2010.02.001, 20430307.
Reich K, Papp KA, Griffiths CEM, Szapary PO, Yeilding N, Wasfi Y, Ott E, Hsu M-C, Lebwohl M, Gordon KB. An update on the long-term safety experience of ustekinumab: results from the psoriasis clinical development program with up to four years of follow-up. J Drugs Dermatol 2012, 11:300-312.
Kary S, Burmester GR. Anakinra: the first interleukin-1 inhibitor in the treatment of rheumatoid arthritis. Int J Clin Pract 2003, 57:231-234.
Strangfeld A, Hierse F, Rau R, Burmester G-R, Krummel-Lorenz B, Demary W, Listing J, Zink A. Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT. Arthritis Res Ther 2010, 12:R5. 10.1186/ar2904, 2875631, 20064207.
Venkiteshwaran A. Tocilizumab. MAbs 2009, 1:432-8. 10.4161/mabs.1.5.9497, 2759492, 20065633.
Dixon WG, Watson KD, Lunt M, Mercer LK, Hyrich KL, Symmons DPM. Influence of anti-tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: results from the British Society for Rheumatology Biologics Register. Arthritis Care Res (Hoboken) 2010, 62:755-763.